瑞芬太尼或舒芬太尼与依托咪酯静脉诱导对老年患者全麻诱导后低血压发生率的影响

注册号:

Registration number:

ChiCTR1900027271 

最近更新日期:

Date of Last Refreshed on:

2019-11-07 14:24:42 

注册时间:

Date of Registration:

2019-11-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

瑞芬太尼或舒芬太尼与依托咪酯静脉诱导对老年患者全麻诱导后低血压发生率的影响

Public title:

Comparison of effects of intravenous remifentanil and sufentanil with etomidate on the incidence of hypotension after induction in elderly patients under general anesthesia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

瑞芬太尼或舒芬太尼与依托咪酯静脉诱导对老年患者全麻诱导后低血压发生率的影响

Scientific title:

Comparison of effects of introvenous remifentanil and sufentanil with etomidate on the incidence of hypotension after induction in elderly patients under general anesthesia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郑栋煜 

研究负责人:

李永华 

Applicant:

Dongyu Zheng 

Study leader:

Yonghua Li 

申请注册联系人电话:

Applicant telephone:

+86 13795208797

研究负责人电话:

Study leader's
telephone:

+86 13795439726

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

brickyu@126.com

研究负责人电子邮件:

Study leader's E-mail:

liyonghua1207@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市凤阳路415号

研究负责人通讯地址:

上海市凤阳路415号

Applicant address:

415 Fengyang Road, Shanghai, China

Study leader's address:

415 Fengyang Road, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

200003

研究负责人邮政编码:

Study leader's postcode:

200003

申请人所在单位:

上海长征医院麻醉科

Applicant's institution:

Department of Anesthesiology, Shanghai Changzheng Hospital

研究负责人所在单位:

上海长征医院麻醉科

Affiliation of the Leader:

Department of Anesthesiology, Shanghai Changzheng Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CZEC(2019)-05

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海长征医院医学伦理委员会

Name of the ethic committee:

Shanghai Changzheng Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2019-09-30 00:00:00

伦理委员会联系人:

郑玮杰

Contact Name of the ethic committee:

Weijie Zheng

伦理委员会联系地址:

上海市凤阳路415号

Contact Address of the ethic committee:

415 Fengyang Road, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海长征医院

Primary sponsor:

Shanghai Changzheng Hospital

研究实施负责(组长)单位地址:

上海市凤阳路415号

Primary sponsor's address:

415 Fengyang Road, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

黄浦区

Country:

China

Province:

Shanghai

City:

Huangpu District

单位(医院):

长征医院

具体地址:

凤阳路415号

Institution
hospital:

Shanghai Changzheng Hospital

Address:

415 Fengyang Road

经费或物资来源:

上海市人才发展资金

Source(s) of funding:

the development fund for Shanghai talents

研究疾病:

全麻诱导后低血压  

Target disease:

hypotension after induction under general anesthesia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过比较瑞芬太尼或舒芬太尼与依托咪酯静脉诱导后低血压的发生率,探索更适合老年患者全麻诱导需要的理想药物。  

Objectives of Study:

To compare the effects of introvenous remifentanil and sufentanil with etomidate on the incidence of hypotension after induction in elderly patients under general anesthesia and to seek the more appropriate induction ansthetic drugs in elderly patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 对丙泊酚、依托咪酯或其它本研究用药过敏者;
2. 近期有呼吸系统感染、哮喘等肺疾患的患者;
3. 严重肝肾功能障碍患者;
4. 颈动脉中重度狭窄患者;
5. 严重窦缓(HR<50次/分)及二度II型房室传导阻滞。

Exclusion criteria:

1. Anaphylaxis to propofol, etomidate or other drugs used in this study;
2. Patients with respiratory system infection, asthma and other lung diseases;
3. Patients with severe liver and kidney dysfunction;
4. Patients with moderate and severe carotid artery stenosis;
5. Severe sinus bradycardia (HR <50 beats/ min) and second degree atrioventricular block.

研究实施时间:

Study execute time:

From 2019-11-11 00:00:00 To 2020-02-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-11-11 00:00:00 To 2020-02-29 00:00:00

干预措施:

Interventions:

组别:

A

样本量:

100

Group:

A

Sample size:

干预措施:

舒芬太尼+依托咪酯

干预措施代码:

Intervention:

Sufentanil plus etomidate

Intervention code:

组别:

B

样本量:

100

Group:

B

Sample size:

干预措施:

瑞芬太尼+依托咪酯

干预措施代码:

Intervention:

Remifentanil plus etomidate

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

黄浦区 

Country:

China

Province:

Shanghai

City:

Huangpu District

单位(医院):

长征医院 

单位级别:

三甲 

Institution
hospital:

Changzheng Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

诱导后低血压发生率

指标类型:

主要指标

Outcome:

incidence of hypotension after induction

Type:

Primary indicator

测量时间点:

插管后10分钟

测量方法:

有创动脉压

Measure time point of outcome:

10 minutes after intubation

Measure method:

Invasive arterial pressure

指标中文名:

插管后心率

指标类型:

主要指标

Outcome:

heart rate after intubation

Type:

Primary indicator

测量时间点:

插管后3分钟以内

测量方法:

philips 监护仪

Measure time point of outcome:

within 3 minutes after intubation

Measure method:

philips

指标中文名:

插管后血压

指标类型:

主要指标

Outcome:

blood pressure after intubation

Type:

Primary indicator

测量时间点:

插管后3分钟以内

测量方法:

philips 监护仪

Measure time point of outcome:

within 3 minutes after intubation

Measure method:

philips

指标中文名:

插管后丙泊酚病例数

指标类型:

次要指标

Outcome:

number of cases of propofol after intubation

Type:

Secondary indicator

测量时间点:

插管后3分钟以内

测量方法:

Measure time point of outcome:

within 3 minutes after intubation

Measure method:

指标中文名:

插管后应用升压药例数

指标类型:

次要指标

Outcome:

number of cases of pressor drugs

Type:

Secondary indicator

测量时间点:

插管后10分钟

测量方法:

Measure time point of outcome:

10 minutes after intubation

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本试验将指将由计算机软件进行随机分组,详细分组表由海军军医大学统计教研室叶小飞教授提供。叶小飞教授不参与具体试验,只负责随机分组和数据统计。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number tables were generated by the computer software and they were provided by Professor Ye Xiaofei, Department of Statistics, Naval military Medical University. Professor Ye Xiaofei will not participate in specific experiments.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲:对患者和数据采集人员采用盲法,实施麻醉者不采用盲法。应用计算机软件分为两组。术前A医生访视签字不告知患者具体分组,B医生负责临床麻醉用“药”,C医生负责记录血流动力学参数及其他相关数据,所有数据汇总后交由专职统计人员处理。

Blinding:

Double blindness: Blind methods will be used for patients and data collectors, and blind methods will not be used for anesthesiologists. Patients will be divided into two groups. Before operation, Dr. A does not inform the patients of the specific grouping, Dr. B is responsible for clinical anesthetic "drugs", Dr. C will be responsible for recording hemodynamic parameters and other related data, and all the data will be collected and handed over to full-time statisticians.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

网络公开 http://pan.baidu.com/share/manage

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

network http://pan.baidu.com/share/manage

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

全麻诱导过程用数码相机全程录像,然后根据每个视频形成一份病历记录表CRF的数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

General anesthesia induction was recorded by digital camera. Later, a medical record table CRF, was formed according to the content of the video。

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-11-07 14:24:43